公开(公告)号：US20130150357A1

公开(公告)日：2013-06-13

申请号：US13680710

申请日：2012-11-19

Applicant: Research Triangle Institute ,  Digital Health d/b/a St. Joseph's Hospital and Med ,  Virginia Commonwealth University

Inventor： F. Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

公开(公告)号：US09750738B2

公开(公告)日：2017-09-05

申请号：US14968258

申请日：2015-12-14

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Frank Ivy Carroll ,  Juan P. Cueva ,  James B. Thomas ,  S. Wayne Mascarella ,  Scott P. Runyon

IPC: A61K31/495 ,  A61K31/496 ,  C07D241/04 ,  C07D401/12 ,  C07D295/096

CPC classification number: A61K31/495 ,  A61K31/496 ,  C07D241/04 ,  C07D295/096 ,  C07D401/12

Abstract: Provided are opioid receptor antagonists represented by the formula (I): where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.

公开(公告)号：US11292783B2

公开(公告)日：2022-04-05

申请号：US16333849

申请日：2017-09-15

Applicant: Research Triangle Institute

Inventor： Frank Ivy Carroll ,  Chad M. Kormos ,  Pauline W. Ondachi ,  Scott P. Runyon ,  Hernan A. Navarro ,  James B. Thomas ,  S. Wayne Mascarella

IPC: A61K31/472 ,  C07D217/26 ,  C07D401/12 ,  A61P25/34 ,  A61P25/36 ,  A61P25/32 ,  A61P25/18 ,  A61P25/24 ,  C07D211/18 ,  C07D413/12 ,  C07D487/08 ,  A61P25/00

Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.

公开(公告)号：US20150141416A1

公开(公告)日：2015-05-21

申请号：US14537124

申请日：2014-11-10

Applicant: Research Triangle Institute ,  Dignity Health d/b/a St. Joseph's Hospital and Medical Center and Barrow Neurological Institute ,  Virginia Commonwealth University

Inventor： Frank Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Abstract translation: 本发明提供能够抑制一种或多种单胺再摄取和/或在烟碱型乙酰胆碱受体上作为拮抗剂的羟基安非他丁类似物。 所述化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白和/或可以选择性地结合一种或多种烟碱型乙酰胆碱受体亚型。 这些化合物可用于治疗对单胺水平的修饰和/或烟碱乙酰胆碱受体的拮抗作用有反应的病症，包括药物依赖性，抑郁症和肥胖症。

公开(公告)号：US20150005315A1

公开(公告)日：2015-01-01

申请号：US14364003

申请日：2012-12-10

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Frank I. Carroll ,  James B. Thomas ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Scott P. Runyon ,  Chunyang Jin ,  Chad M. Kormos

IPC: C07D401/12 ,  C07D241/04

CPC classification number: C07D401/12 ,  C07D241/04 ,  C07D295/13

Abstract: Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Abstract translation: 提供了由下式表示的化合物：其中R，Y3，R1，R2，R3，R4，R6，G，R7，E1，E2，A，B，W，X，Y和Z如本文所定义。

公开(公告)号：US20190263781A1

公开(公告)日：2019-08-29

申请号：US16333849

申请日：2017-09-15

Applicant: Research Triangle Institute

Inventor： Frank Ivy Carroll ,  Chad M. Kormos ,  Pauline W. Ondachi ,  Scott P. Runyon ,  Hernan A. Navarro ,  James B. Thomas ,  S. Wayne Mascarella

IPC: C07D401/12 ,  C07D413/12 ,  A61P25/18 ,  A61P25/24 ,  A61P25/32 ,  A61P25/34 ,  A61P25/36 ,  C07D217/26 ,  C07D211/18

Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.

公开(公告)号：US09527823B2

公开(公告)日：2016-12-27

申请号：US14537124

申请日：2014-11-10

Applicant: Research Triangle Institute ,  Dignity Health ,  Virginia Commonwealth University

Inventor： Frank Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32 ,  A61K31/5375

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogs capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Abstract translation: 本发明提供了能够抑制一种或多种单胺再摄取和/或在烟碱乙酰胆碱受体上作为拮抗剂的羟基安非他丁类似物。 所述化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白和/或可以选择性地结合一种或多种烟碱型乙酰胆碱受体亚型。 这些化合物可用于治疗对单胺水平的修饰和/或烟碱乙酰胆碱受体的拮抗作用有反应的病症，包括药物依赖性，抑郁症和肥胖症。

公开(公告)号：US09512105B2

公开(公告)日：2016-12-06

申请号：US14364003

申请日：2012-12-10

Applicant: RESEARCH TRIANGLE INSTITUTE

Inventor： Frank I. Carroll ,  James B. Thomas ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Scott P. Runyon ,  Chunyang Jin ,  Chad M. Kormos

IPC: C07D241/04 ,  C07D401/12 ,  C07D295/13

CPC classification number: C07D401/12 ,  C07D241/04 ,  C07D295/13

Abstract: Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

公开(公告)号：US08906908B2

公开(公告)日：2014-12-09

申请号：US13680710

申请日：2012-11-19

Applicant: Research Triangle Institute ,  Dignity Health ,  Virginia Commonwealth University

Inventor： F. Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32 ,  A61K31/5375

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Abstract translation: 本发明提供能够抑制一种或多种单胺再摄取和/或在烟碱型乙酰胆碱受体上作为拮抗剂的羟基安非他丁类似物。 所述化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白和/或可以选择性地结合一种或多种烟碱型乙酰胆碱受体亚型。 这些化合物可用于治疗对单胺水平的修饰和/或烟碱乙酰胆碱受体的拮抗作用有反应的病症，包括药物依赖性，抑郁症和肥胖症。